tuneTypical Dose
About 10^9 to 10^11 CFU/day depending on strain/indication
Microbiome Modulator
Probiotics
Live microorganisms conferring host benefit when administered in adequate amounts
Evidence TierBWADA NOT PROHIBITED
watchEffect Window
Days-to-weeks for AAD prevention. About 4-12 weeks for IBS symptom endpoints.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Probiotics are live microorganisms intended to confer health benefits when taken in adequate amounts. Their value is strain-specific, with the clearest evidence in antibiotic-associated diarrhea prevention.
Strain-specific evidence supports reduced antibiotic-associated diarrhea and some improvement in IBS symptom burden, although the IBS evidence remains heterogeneous and low certainty across strains and formulations even in updated 2026 pooled data. Certain strains support vaginal and urinary outcomes, but class-wide claims are unreliable. Many products lack clinically studied strains, and high-risk hosts face meaningful safety exceptions.
Live strains modulate microbiome ecology, pathogen resistance, and mucosal signaling, but effects are highly strain, dose, timing, and population dependent.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduced antibiotic-associated diarrhea risk
- Reduced C. difficile-associated diarrhea risk in higher-risk antibiotic settings
Secondary Outcomes
- Possible IBS pain/bloating improvement (strain-dependent)
- Mixed efficacy outside validated indications
Safety
Contraindications and Interactions
Contraindications
- Severe immunocompromise without specialist oversight
- Critical illness/central-line settings
- Prior severe probiotic-related infection event
Side effects
- Gas and bloating
- Mild GI discomfort
- Rare invasive infection in high-risk hosts
Interactions
- Antibiotics can reduce probiotic viability if co-timed
- Antifungals reduce efficacy of Saccharomyces products
- Multi-probiotic stacking can increase GI symptoms/confound attribution
Avoid if
- Critically ill or severely debilitated patients without supervision
- Very frail elderly high-risk contexts
- Non-evidence-based multi-strain polypharmacy
Evidence
Study-level References
probiotics-SRC-001Expert consensus.
Sourceopen_in_newHill C, et al. Expert consensus document. The ISAPP consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. doi:10.1038/nrgastro.2014.66. PMID:24912386.
Population: Terminology, scope, and appropriate probiotic-claim framework.
Dose protocol: Not applicable.
Key findings: Reinforces live, adequate-dose, proven-benefit criteria.
Notes: Not an efficacy trial. Foundational classification source.
Paper content
Reinforces live, adequate-dose, proven-benefit criteria.
probiotics-SRC-002Systematic review and meta-analysis of randomized controlled trials
Sourceopen_in_newGoodman C, Keating G, Georgousopoulou E, Hespe C, Levett K. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open. 2021;11(8):e043054. doi:10.1136/bmjopen-2020-043054. PMID:34385227.
Population: Adults receiving antibiotics across 42 randomized trials.
Dose protocol: Mixed strains and doses. Probiotic co-administered with antibiotics.
Key findings: Significant AAD risk reduction.
Notes: Moderate-certainty overall. Heterogeneity by baseline risk/species/dose.
Paper content
This adult-only systematic review and meta-analysis updated the probiotic AAD literature with 42 randomized trials involving 11,305 participants. The pooled estimate suggested a 37% relative reduction in antibiotic-associated diarrhea risk (RR 0.63, 95% CI 0.54-0.73), with moderate GRADE certainty.
The review also found that higher-dose protocols and some Lactobacillus- or Bifidobacterium-dominant interventions appeared more effective than lower-dose or less specific approaches, while low-baseline-risk settings showed little clear benefit. It is useful because it modernizes the adult-only signal and keeps the message appropriately narrow: probiotic benefit depends on baseline risk, dose, and strain selection rather than the label alone.
probiotics-SRC-003Cochrane systematic review and meta-analysis.
Sourceopen_in_newGoldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12:CD006095. doi:10.1002/14651858.CD006095.pub4. PMID:29257353.
Population: 39 trials, 9955 participants.
Dose protocol: Any probiotic strain/dose versus controls with antibiotic exposure.
Key findings: Reduced CDI incidence, with larger effect at higher baseline CDI risk.
Notes: Moderate certainty for main CDI-prevention outcome. Heterogeneity explored.
Paper content
Reduced CDI incidence, with larger effect at higher baseline CDI risk.
probiotics-SRC-004Systematic review with meta-regression.
Sourceopen_in_newShen NT, et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology. 2017;152(8):1889-1900.e9. doi:10.1053/j.gastro.2017.02.003. PMID:28192108.
Population: 19 studies, 6261 hospitalized adults.
Dose protocol: Probiotic prophylaxis timing relative to antibiotic start.
Key findings: Earlier initiation associated with stronger CDI prevention.
Notes: Hospital-focused context. Timing analysis adds actionable insight.
Paper content
Earlier initiation associated with stronger CDI prevention.
probiotics-SRC-005Systematic review and meta-analysis.
Sourceopen_in_newKonstantis G, et al. Efficacy and safety of probiotics in the treatment of irritable bowel syndrome: meta-analysis of RCTs using ROME IV criteria. Clin Nutr. 2023;42(5):800-809. doi:10.1016/j.clnu.2023.03.019. PMID:37031468.
Population: 6 double-blind placebo-controlled RCTs (970 participants) using Rome IV diagnosis.
Dose protocol: Nine probiotic strains across trials.
Key findings: Benefit on pain/bloating. Inconsistent effect on overall IBS severity and QoL.
Notes: High heterogeneity and limited trial count for strict Rome IV subgroup.
Paper content
Benefit on pain/bloating; inconsistent effect on overall IBS severity and QoL.
probiotics-SRC-006Systematic review and meta-analysis.
Sourceopen_in_newZhang WX, et al. Efficacy of probiotics, prebiotics and synbiotics in IBS: systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. J Med Microbiol. 2023;72(9):001758. doi:10.1099/jmm.0.001758. PMID:37772692.
Population: 52 trials, 6289 IBS patients.
Dose protocol: Mixed species/formulations and dosing regimens.
Key findings: Probiotics improved selected IBS response outcomes. Prebiotic/synbiotic data less certain.
Notes: Broad inclusion with substantial heterogeneity.
Paper content
Probiotics improved selected IBS response outcomes; prebiotic/synbiotic data less certain.
probiotics-SRC-007Retrospective case series.
Sourceopen_in_newPoncelet A, et al. Saccharomyces cerevisiae fungemia: Risk factors, outcome and links with S. boulardii-containing probiotic administration. Infect Dis Now. 2021;51(3):293-295. doi:10.1016/j.idnow.2020.12.003. PMID:33934809.
Population: 10 fungemia cases in a hospital setting.
Dose protocol: Clinical cases with/without S. boulardii probiotic exposure.
Key findings: Rare but serious safety signal in high-risk hosts.
Notes: Observational case-series. No randomized causality.
Paper content
Rare but serious safety signal in high-risk hosts.
probiotics-SRC-008Systematic review and meta-analysis with trial sequential analysis
Sourceopen_in_newTang ASP, Quek J, Sulaimi F, Sim B, Kai TOS, Soon EY, Goh CN, Hsu JLJ, Lee CKL, Chong SKS, Sule AA, Ling RR, Siah KTH, Ng QX. Probiotics for Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis With Trial Sequential Analysis. J Gastroenterol Hepatol. 2026 Mar 12. doi:10.1111/jgh.70322. PMID:41820241.
Population: Adults with irritable bowel syndrome enrolled in 40 randomized placebo-controlled probiotic trials.
Dose protocol: Varied strains and formulations across 40 placebo-controlled IBS trials.
Key findings: Updated meta-analysis found lower IBS symptom severity with probiotics, but trial sequential analysis showed the evidence base is still underpowered and inconsistent.
Notes: This strengthens the rationale for cautious, strain-specific IBS wording rather than stronger efficacy claims.
Paper content
Updated pooled evidence suggests probiotics can reduce IBS symptom severity, but the review explicitly found that the information size remains insufficient and the certainty of evidence stays low because of inconsistency across strains and trials.
probiotics-SRC-009Systematic review and meta-analysis of clinical trials
Sourceopen_in_newYang R, Jiang J, Ouyang J, Zhao Y, Xi B. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Clin Nutr ESPEN. 2024;60:362-372. doi:10.1016/j.clnesp.2024.02.025. PMID:38479936.
Population: Adults with irritable bowel syndrome across 20 controlled studies.
Dose protocol: Mixed IBS probiotic regimens, with subgroup signals favoring higher-dose or multi-strain products.
Key findings: Meta-analysis found better global response and quality of life, with abdominal-pain benefit in higher-dose or multi-strain protocols.
Notes: Heterogeneity remained high, so this supports cautious IBS wording rather than class-wide certainty.
Paper content
Updated pooled IBS data suggested probiotics modestly improve global response and quality of life, with larger abdominal-pain signals in higher-dose or multi-strain protocols, but heterogeneity remained high.